Tag: VIVA 2025
‘We need to look at the totality of evidence’: VIVA panelists...
A focused session at the 2025 Vascular Interventional Advances (VIVA) conference (2–5 November, Las Vegas, USA) homed in on the latest findings from the...
PROMISE III: Six-month data ‘reinforce’ case for TADV in no-option CLTI...
Six-month outcomes among no-option chronic limb-threatening ischemia (CLTI) patients treated using transcatheter arterialization of the deep veins with the LimFlow system (Stryker/Inari Medical) in...
PERFORMANCE III demonstrates ‘very low’ 30-day event rates for dual neuroprotection...
Thirty-day results from the PERFORMANCE III study of integrated embolic protection (IEP) in transcarotid artery revascularization (TCAR) demonstrate “very low” 30-day event rates. Sean...
‘Excellent’ one-year outcomes from ROADSTER 3 show TCAR is ‘safe and...
One-year outcomes in the ROADSTER 3 post-approval study to evaluate the safety and effectiveness of transcarotid artery revascularization (TCAR) using the Enroute stent and...